Skip to search formSkip to main contentSkip to account menu

lesinurad Oral Tablet [Zurampic]

National Institutes of Health

Related topics

Related topics

3 relations
Oral TabletZurampic

Broader (1)

Zurampic Pill

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Lesinurad in hyperuricaemia of gout: a profile of its use in the EU
Up to 90% of gout patients experience low uric acid (UA) excretion rather than high UA production. The selective UA reabsorption… 
2017
2017
Case History: Zurampic® (Lesinurad): A Selective Uric Acid Reabsorption Inhibitor for the Treatment of Hyperuricemia in Gout Patients
Review
2016
Review
2016
Lesinurad: First Global Approval
Lesinurad (ZURAMPIC®) is an oral urate–anion exchanger transporter 1 (URAT1) inhibitor developed by Ardea Biosciences (a… 
2016
2016
Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)